论文部分内容阅读
目的分析三阴性乳腺癌与Luminal A型乳腺癌血清中micro RNA-21与micro RNAlet-7a的表达。方法 40例女性乳腺癌患者,其中20例三阴性乳腺癌患者作为观察组,另20例Luminal A型乳腺癌患者作为对照组,另选取同时期体检结果健康的20例女性作为健康组。检测三组血清中的mi RNA-21与micro RNAlet-7a表达水平。结果观察组血清的micro RNA-21水平分别高于对照组和健康组(P<0.05)。观察组、对照组与健康组血清中的micro RNAlet-7a表达水平分别为(0.06±0.03)、(0.09±0.07)、(0.14±0.13),观察组血清中的micro RNAlet-7a表达水平低于健康组(P<0.05)。观察组Ⅰ期micro RNA-21的表达量明显低于Ⅱ~Ⅲ期的表达量,差异具有统计学意义(P<0.05)。结论 micro RNA-21与micro RNAlet-7a的表达水平可作为三阴性乳腺癌特异性治疗的候选靶点。
Objective To analyze the expression of micro RNA-21 and micro RNAlet-7a in the serum of triple-negative breast cancer and Luminal A breast cancer. Methods Forty female breast cancer patients, including 20 cases of triple negative breast cancer patients as observation group and the other 20 cases of Luminal A breast cancer as control group, were selected as the healthy group. The levels of mi RNA-21 and microRNAlet-7a in serum of three groups were detected. Results The level of micro RNA-21 in observation group was higher than that in control group and healthy group (P <0.05). The microRNAlet-7a expression levels in the observation group, the control group and the healthy group were (0.06 ± 0.03), (0.09 ± 0.07), (0.14 ± 0.13), respectively. The serum microRNAlet-7a expression level in the observation group was lower than Healthy group (P <0.05). The expression of microRNA-21 in stage Ⅰ of observation group was significantly lower than that of stage Ⅱ ~ Ⅲ, the difference was statistically significant (P <0.05). Conclusion The expression level of microRNA-21 and micro RNAlet-7a may serve as potential targets for the specific treatment of triple-negative breast cancer.